IMMUNITYBIO, INC. Investment Income, Net
IMMUNITYBIO, INC. (IBRX) reported Investment Income, Net of $8.94 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-14.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2021-05-14
- IMMUNITYBIO, INC. investment income, net for the quarter ending 2021-03-31 was $8.94M, a 11366.67% increase year-over-year.
- IMMUNITYBIO, INC. investment income, net for the quarter ending 2020-12-31 was $2.12M, a 91.32% increase year-over-year.
- IMMUNITYBIO, INC. investment income, net for the quarter ending 2020-09-30 was $66.00K, a 84.76% decline year-over-year.
- IMMUNITYBIO, INC. investment income, net for the quarter ending 2020-06-30 was $75.00K, a 85.93% decline year-over-year.
- IMMUNITYBIO, INC. investment income, net for fiscal 2018 was $1.86M, a 30.32% decline from fiscal 2017.
- IMMUNITYBIO, INC. investment income, net for fiscal 2017 was $2.67M, a 13.95% decline from fiscal 2016.
- IMMUNITYBIO, INC. investment income, net for fiscal 2016 was $3.10M, a 3.65% increase from fiscal 2015.
- IMMUNITYBIO, INC. investment income, net for fiscal 2015 was $2.99M, a 14840.00% increase from fiscal 2014.
| Period end | Investment Income, Net 3 month | Investment Income, Net 3 month as first filed | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month | Investment Income, Net 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-03-31 | $8.94M 10-Q · filed 2021-05-14 | $11.06M derived: sum of 2 quarters · filed 2021-05-14 | $11.13M derived: sum of 3 quarters · filed 2021-05-14 | $11.20M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2020-12-31 | $2.12M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $2.18M derived: sum of 2 quarters · filed 2021-04-22 | $2.26M derived: sum of 3 quarters · filed 2021-04-22 | $2.44M 8-K/A · filed 2021-04-22 | $366.00K 10-K · filed 2021-03-04 | |
| 2020-09-30 | $66.00K 10-Q · filed 2020-11-09 | $141.00K derived: sum of 2 quarters · filed 2020-11-09 | $319.00K 10-Q · filed 2020-11-09 | $1.32M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2020-06-30 | $75.00K 10-Q · filed 2020-08-07 | $253.00K 10-Q · filed 2020-08-07 | $1.26M derived: sum of 3 quarters · filed 2021-05-14 | $1.69M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2020-03-31 | $78.00K 10-Q · filed 2021-05-14 | $178.00K 10-Q · filed 2020-05-11 | $1.18M derived: sum of 2 quarters · filed 2021-05-14 | $1.62M derived: sum of 3 quarters · filed 2021-05-14 | $2.15M derived: sum of 4 quarters · filed 2021-05-14 | |
| 2019-12-31 | $1.11M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $1.54M derived: sum of 2 quarters · filed 2021-04-22 | $2.07M derived: sum of 3 quarters · filed 2021-04-22 | $2.44M 8-K/A · filed 2021-04-22 | $1.64M 10-K · filed 2020-03-25 | |
| 2019-09-30 | $433.00K 10-Q · filed 2020-11-09 | $966.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.34M 10-Q · filed 2020-11-09 | $1.75M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-06-30 | $533.00K 10-Q · filed 2020-08-07 | $903.00K 10-Q · filed 2020-08-07 | $1.32M derived: sum of 3 quarters · filed 2021-03-04 | $1.76M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-03-31 | $370.00K 10-Q · filed 2020-05-11 | $785.00K derived: sum of 2 quarters · filed 2021-03-04 | $1.23M derived: sum of 3 quarters · filed 2021-03-04 | $1.72M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2018-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $862.00K derived: sum of 2 quarters · filed 2021-03-04 | $1.35M derived: sum of 3 quarters · filed 2021-03-04 | $1.86M 10-K · filed 2021-03-04 | ||
| 2018-09-30 | $447.00K 10-Q · filed 2019-11-05 | $937.00K derived: sum of 2 quarters · filed 2019-11-05 | $1.44M 10-Q · filed 2019-11-05 | $1.97M derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2018-06-30 | $490.00K 10-Q · filed 2019-08-06 | $995.00K 10-Q · filed 2019-08-06 | $1.52M derived: sum of 3 quarters · filed 2020-03-25 | $2.20M derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2018-03-31 | $505.00K 10-Q · filed 2019-05-08 | $1.03M derived: sum of 2 quarters · filed 2020-03-25 | $1.71M derived: sum of 3 quarters · filed 2020-03-25 | $2.39M derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2017-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $1.21M derived: sum of 2 quarters · filed 2020-03-25 | $1.89M derived: sum of 3 quarters · filed 2020-03-25 | $2.67M 10-K · filed 2020-03-25 | ||
| 2017-09-30 | $680.00K 10-Q · filed 2018-11-07 | $1.36M derived: sum of 2 quarters · filed 2018-11-07 | $2.14M 10-Q · filed 2018-11-07 | $2.94M derived: sum of 4 quarters · filed 2019-03-13 | ||
| 2017-06-30 | $681.00K 10-Q · filed 2018-08-06 | $1.46M 10-Q · filed 2018-08-06 | $2.25M derived: sum of 3 quarters · filed 2019-03-13 | $3.05M derived: sum of 4 quarters · filed 2019-03-13 | ||
| 2017-03-31 | $779.00K 10-Q · filed 2018-05-07 | $1.57M derived: sum of 2 quarters · filed 2019-03-13 | $2.37M derived: sum of 3 quarters · filed 2019-03-13 | $3.11M derived: sum of 4 quarters · filed 2019-03-13 | ||
| 2016-12-31 | $795.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $1.59M derived: sum of 2 quarters · filed 2019-03-13 | $2.33M derived: sum of 3 quarters · filed 2019-03-13 | $3.10M 10-K · filed 2019-03-13 | ||
| 2016-09-30 | $795.00K 10-Q · filed 2017-11-07 | $1.53M derived: sum of 2 quarters · filed 2017-11-07 | $2.30M 10-Q · filed 2017-11-07 | $5.14M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-06-30 | $739.00K 10-Q · filed 2017-08-07 | $1.51M 10-Q · filed 2017-08-07 | $4.35M derived: sum of 3 quarters · filed 2018-03-12 | $4.43M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-03-31 | $768.00K 10-Q · filed 2017-05-08 | $3.61M derived: sum of 2 quarters · filed 2018-03-12 | $3.69M derived: sum of 3 quarters · filed 2018-03-12 | $3.72M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $2.92M derived: sum of 2 quarters · filed 2018-03-12 | $2.96M derived: sum of 3 quarters · filed 2018-03-12 | $2.99M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $81.00K 10-Q · filed 2016-11-10 | $114.00K derived: sum of 2 quarters · filed 2016-11-10 | $146.00K 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | $33.00K 10-Q · filed 2016-08-15 | $65.00K 10-Q · filed 2016-08-15 | ||||
| 2015-03-31 | $32.00K 10-Q · filed 2016-05-16 | |||||
| 2014-12-31 | $20.00K 10-K · filed 2017-03-15 | |||||
| 2013-12-31 | $2.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |